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Abstract
Background: When to initiate antiretroviral therapy in HIV infected patients is a diffcult clinical decision. Actually, it
is still a matter of discussion whether early highly active antiretroviral therapy (HAART) during primary HIV infection
may influence the dynamics of the viral rebound, in case of therapy interruption, and overall the main disease
course.
Methods: In this article we use a computational model and clinical data to identify the role of HAART timing on
the residual capability to control HIV rebound after treatment suspension. Analyses of clinical data from three
groups of patients initiating HAART respectively before seroconversion (very early), during the acute phase (early)
and in the chronic phase (late), evidence differences arising from the very early events of the viral infection.
Results: The computational model allows a fine grain assessment of the impact of HAART timing on the disease
outcome, from acute to chronic HIV-1 infection. Both patients’ data and computer simulations reveal that HAART
timing may indeed affect the HIV control capability after treatment discontinuation. In particular, we find a median
time to viral rebound that is significantly longer in very early than in late patients.
Conclusions: A timing threshold is identified, corresponding to approximately three weeks post-infection, after
which the capability to control HIV replication is lost. Conversely, HAART initiation occurring within three weeks
from the infection could allow to preserve a significant control capability. This time could be related to the global
triggering of uncontrolled immune activation, affecting residual immune competence preservation and HIV
reservoir establishment.
Background
The question of when antiretroviral therapy has to be
initiated remains a challenging issue. Recent studies
show that the early immune response to HIV-1 infection
is likely to be an important factor in determining the
clinical course of disease [1]. The first weeks following
HIV-1 transmission are extremely dynamic. They are
associated with rapid damage to generative immune cell
micro-environments and with immune responses that
partially control the virus. Following HIV-1 infection,
the virus first replicates locally in the mucosa and then
is transported to draining lymph nodes where further
amplification occurs. This initial phase of infection, until
the systemic viral dissemination begins, constitutes the
eclipse phase [1]. In general, there is an exponential
increase in plasma viremia with a peak 21-28 days after
infection. By this time, significant depletion of mucosal
CD4
+T cells has already occurred. Around the time of
peak viremia, patients may become symptomatic and
reservoirs of latent virus are established [1,2].
The “window of opportunity” between the infection
and peaking of viremia, prior to massive CD4
+ Tc e l l
destruction and the establishment of viral reservoirs,
seems to be a narrow but crucial period in which an
antiretroviral therapy can control viral replication, pre-
vent an extensive CD4
+ T cell depletion from occurring
and curb generalized immune activation. Thus, thwart-
ing HIV replication by introducing HAART in the early
phases of infection could have a substantial impact on
the whole disease course. In particular, suggested factors
that may contribute to the observed better viral control
after treatment interruption in very early treated
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any medium, provided the original work is properly cited.patients are [3]: i) early arrest of viral escape, leaving the
virus vulnerable; ii) preservation or even enhancement
of the immune response resulting from the early clear-
ing of antigen; iii) prevention of the establishment of a
pool of HIV-specific memory CD4 T cells thus leaving
fewer target cells available for viral infection.
An ideal clinical model aimed at addressing such issue
should compare a number of patients treated starting
on different times: from very early to very late. Besides
the ethical issues, it is rather difficult to collect enough
patients to significantly represent the whole spectrum of
possible HAART initiation timings. As a matter of fact,
a practical clinical model would compare very early to
late-treated patients. While informative on the overall
role of HAART timing on disease course, this approach
would not allow to verify if there are events in the early
infection influenced by the starting time of HAART that
affect directly and decisively the course of the disease.
We have already shown in [4-6] that an agent-based
model of HIV-1 infection could be a valuable tool for the
study of the AIDS disease progression and treatment.
The computerized simulation allows us to track the effect
of HAART timing on the progression of the disease.
The aim of the present work is to verify the effect of
HAART timing on subsequent events. Indeed, both a
clinical model and a computational simulation show that
a late initiation of treatment affects HIV-1 replication
control. Interestingly, the in silico model identifies a sig-
nificant three-week time threshold as the “ultimate” time
point beyond which the decisive HIV-induced damages
already occurred, affecting the whole disease course.
I nap r e v i o u sw o r k[ 4 ] ,w ea n a l y z e dc l i n i c a ld a t ao f
patients initiating HAART within six months from
infection (i.e., we called that early phase) and performed
computer simulations to predict the differences in viral
rebound at therapy interruption between those patients
and subjects initiating therapy during the chronic phase
(i.e., we called that late phase, corresponding to initiat-
ing six or more months after infection). Our conclusion
was that early initiation of therapy does not prolong the
disease-free period when compared to a treatment
started during the late phase. However, other studies
suggest that an earlier initiation is preferable [7-9]. This
motivated us to better identify the meaning of early
initiation. In the present article, we extend the analysis
i n[ 4 ]t og e tam o r ec o m p l e t ep i c t u r e .W ea n a l y z ec l i n i -
cal data of very early patients (i.e., treated before sero-
convertion) against late-treated patients.
Methods
Clinical studies
We analyzed the results of clinical studies performed at
the Clinical Department of the National Institute for
Infectious Disease “L. Spallanzani” in Rome.
A first group of eleven patients (9 male and 2 female)
were diagnosed HIV-1 positive between year 1998 and
2006. All patients initiated HAART within 14 days from
diagnosis, during the very early phase of infection (see
Table 1). The very early phase was defined as having a
negative or indeterminate western blot for HIV-1 anti-
bodies in combination with a positive test for either p24
antigen or a detectable HIV-1 RNA concentration.
Those patients were treated with zidovudine/lamivudine
(CBV) in combination with either the reverse transcrip-
tase inhibitor efavirenz (EFZ) or one protease inhibitor
lopinavir/ritonavir (KAL) or indinavir (IDV). Because
anaemia and neutropenia were diagnosed, in two cases
CBV has been substituted with lamivudine (3TC) and
staduvine (D4T). All those patients underwent a therapy
cycle for 2 ± 1 years and remained off HAART for
about 48 weeks.
The second group is made up by twenty-two patients
(21 male and 1 female) enrolled in the program between
year 1998 and 2005. Patients in this group underwent
HAART during the early phase of HIV-1 infection. In
particular, they started HAART about 20 days after
treatment diagnosis (see Table 2). Early patients were
defined as having documented seronegative HIV-1 anti-
body test within the previous 6 months; acute sympto-
matic seroconversion illness; evolving HIV-specific
antibody response by ELISA; positive HIV-DNA PCR in
PBMC. Those patients were treated with three different
drugs (in the majority of cases zidovudine (AZT) plus
3TC plus a protease inhibitor. Further details can be
found in Table One of [4]. All those patients underwent
a therapy cycle for 3 ± 1 years and remained o HAART
for about 88 weeks.
The third group consists oft w e n t y - o n ep a t i e n t s
(12 male, 9 female). They started HAART during the
chronic phase of infection defined as suggested by the
guidelines [10]. In particular, they started HAART about
3.5 years after treatment diagnosis (see Table 3). Their
CD4 count at initiation was 400 ± 150 per microlitre of
plasma. The range of calendar year for starting HAART
among those patients was 1998 ± 3. All those patients
underwent a therapy cycle for 4 ± 2 years and remained
off HAART for about 41 weeks. The Ethical Committee
of the “L. Spallanzani” Institute approved the study and
the patients gave a written informed consent.
Plasma HIV-1 determination
Plasma HIV-1 RNA levels were determined by a second-
generation assay based on nucleic acid sequence based
amplification (NASBA), for samples collected until 2001
and by the branched-chain DNA assay (Versant HIV
RNA test, Version 3.0, lower limit of quantification 50
copies/ml; Bayer Diagnostics, Milan, Italy) from 2001
until 2008.
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The current version of the model we employ derives
from an early simulator that has been quite extensively
described in previous publications [11,12]. Recently it
has been specialized to simulate the HIV-1 infection [6]
and the effects of antiretroviral therapy [4].
Briefly, it resorts to bit strings to represent “binding
sites” of cells and molecules, as for example lymphocyte
receptors, MHC, antigen peptides and epitopes, immu-
nocomplexes, etc. [13]. The model includes the major
classes of cells of the lymphoid lineage (T helper lym-
phocytes, cytotoxic T lymphocytes, B lymphocytes and
Table 1 Very early subjects with an immediate treatment before seroconversion
ID Therapy
† therapy Elapsed days
‡ therapy At diagnosis* 4 weeks after** 8 weeks after**
CD4 vRNA CD4 vRNA CD4 vRNA
Pz4 CBV, IDV 14 603 16000 800 < 50 792 6000
Pz34 CBV, EFZ 18 370 280000 647 640 815 < 50
Pz36 CBV, EFZ 15 402 14000 < 50 599 < 50
Pz38 CBV, EFZ 2 543 3500000 1600 770 220
Pz41 CBV, EFZ 12 568 1300000 1549 < 50 857 < 50
Pz42 CBV, EFZ 8 234 1083 2300 657 < 50
Pz47 CBV, IDV 4 753 8802 615 220 743 < 50
Pz51 CBV, EFZ 10 530 91972 655 < 50 810 < 50
Pz67 CBV, KAL 0 797 21675 884 98 932 < 50
Pz83 CBV, KAL 18 426 > 500000 770 2349 1524 1037
Pz113 CBV, KAL 3 261 65716 422 660 460 302
Clinical information about the eleven patients selected at the Clinical Department of the National Institute for Infectious Disease “L. Spallanzani” in Rome. All
subjects received HAART within six months from primary infection.
†CBV, Combivir (AZT Zidovudine plus 3TC Lamivudine); IDV, Indinavir; EFZ, Efavirenz; KAL, Kaletra (lopinavir/ritonavir).
‡ Days elapsed from diagnosis (enrollment)
to initiation of HAART. *CD4 and CD8 are per microlitre of plasma, viremia is per millilitre of plasma. ** 4 weeks after treatment interruption.
Table 2 Early subjects with an immediate treatment of acute HIV-1 infection
ID Therapy
† Elapsed days
‡ Days on therapy Days out therapy At diagnosis* At first interruption
CD4 CD8 vRNA CD4 CD8 vRNA
Pt 03 D4T,3TC,IDV 14 1775 27 653 1659 75 809 459 5794
Pt 05 AZT,3TC,IDV 61 1657 27 444 633 100 867 476 < 50
Pt 29 AZT,3TC,NFV 14 1069 28 1103 1964 31 741 844 < 50
Pt 33 AZT,3TC,IDV 66 925 28 424 991 0.13 458 474 147
Pt 35 AZT,3TC,EFV 1 1041 30 522 1205 78 919 607 496
Pt 37 AZT,3TC,EFV 0 1371 790 545 1233 3.9 901 384 < 50
Pt 58 AZT,3TC,EFV 3 442 27 768 1632 50 1451 1580 < 50
Pt 06 AZT,3TC,IDV 32 1620 1908 882 4146 4.1 754 726 < 50
Pt 18 AZT,3TC,IDV 26 635 213 1319 1810 15 1718 825 < 80
Pt 24 AZT,3TC,IDV 3 1231 542 507 3162 78 513 1067 < 50
Pt 31 AZT,3TC,EFV 19 1102 1654 322 243 490 1154 1165 < 50
Pt 41 AZT,3TC,EFV 12 705 1837 568 278 130 1326 940 < 50
Pt 45 AZT,3TC,EFV 5 488 55 307 1032 130 872 506 < 50
Pt 53 AZT,3TC,Lop/rit 16 503 179 341 779 18.9 545 529 150
Pt 04 AZT,3TC,IDV 6 1561 2155 603 1288 1.6 1047 1015 88
Pt 19 AZT,3TC,IDV 13 1480 1640 1338 716 10 1113 447 < 50
Pt 28 AZT,3TC,NFV 7 325 70 281 860 190 863 485 < 80
Pt 32 AZT,3TC,EFV 15 1384 669 409 1448 4.3 960 331 < 50
Pt 72 AZT,3TC,LPV 7 318 343 827 386 19 1005 751 < 50
Pt 81 AZT,3TC,NVP 33 745 317 412 264 32.5 522 461 68
Pt 85 AZT,3TC,Lop/rit 46 717 717 326 669 50 855 1436 < 50
Pt 92 3TC,Lop/rit,TNF 0 455 331 616 3774 46.3 1027 913 < 50
Clinical information about the twenty-two patients selected at the Clinical Department of the National Institute for Infectious Disease “L. Spallanzani” in Rome. All
subjects received HAART within six months from primary infection.
†D4T, staduvine; 3TC, lamivudine; IDV, Indinavir; AZT, Zidovudine; NFV, nelflnavir; EFV, Efavirenz; NVP, nevirapine; TNF, Tenofovir; Lop, lopinavir; Rit, Ritonavir; LPV
(KAL), Kaletra (lopinavir/ritonavir).
‡ Days elapsed from diagnosis (enrollment) to initiation of HAART. *CD4 and CD8 are per microlitre of plasma, viremia is per
millilitre of plasma.
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Page 3 of 9antibody-producer plasma cells) and some of the mye-
loid lineage (macrophages and dendritic cells). These
entities are individually represented. In contrast to cells,
cytokines like interleukin-2 are represented in terms of
concentrations and their dynamics described by a para-
bolic partial differential equation plus a degradation
term accounting for the finite half-life [5,14]. Modeling
features of the HIV infection include HIV replication
inside infected lymphocytes, T production impairment;
specific response against HIV strains and HIV mutation.
The simulated life cycle of the virus is represented by
the following stages: 1) the virus infects CD4
+ T cells,
macrophages, dendritic cells; 2) reverse transcriptase
copies the viral single stranded RNA genome into a
double-stranded viral DNA. The viral DNA is then inte-
grated into the host chromosomal DNA; 3) the virus
remains at rest until an event activates the transcription;
4) the replicating virus buds from the cell membrane.
Fully assembled virions are then able to infect other
cells to restart the life cycle. HAAR effects are modeled
as follows: Reverse transcriptase inhibitors block reverse
transcriptase enzymatic functions and avoid completion
of synthesis of the double-stranded viral DNA thus pre-
venting HIV-1 from replicating (i.e., it prevents the virus
in stage 1 from reaching stage 2); Protease inhibitors
prevent viral replication by inhibiting the activity of
HIV-1 protease, an enzyme used by the virus to cleave
nascent proteins for final assembly of new virions (i.e., it
prevents virus assembly in stage 4). Further details and
parameter settings of the simulations can be found in
the Additional file 1.
For what concerns the setting of the parameters
related to the therapy, we performed computer simula-
tions in which we fixed the immunological parameters
at the time of therapy initiation on the basis of the aver-
age values measured in patients in vivo: 5.8 ± 0.2 RNA
copies/ml (in logarithmic scale), 870 ± 50 CD4 cells/μl
and 430 ± 50 CD8 cells/μl. For all simulations we
applied a one-year course of HAART. Further details on
the tuning of the simulation parameters can be found in
the Additional file 2.
Results
We analyze virological data from HIV patients treated
during the very early, early and late phase of infection
and compare them with computer simulations.
In Figure 1 clinical data of all three analyzed groups is
shown altogether. In a point-by-point comparison we
Table 3 Late subjects with deferred treatment of acute HIV-1 infection
ID Therapy
† Elapsed days
‡ Days on therapy Days out therapy At diagnosis* At first interruption
CD4 CD8 vRNA CD4 CD8 vRNA
Pt 07 AZT, 3TC 300 1303 606 463 2498 34000 614 3101 9154
Pt 12 D4T, 3TC, SQV 26 1117 89 422 754 62000 601 948 < 50
Pt 16 AZT, ddC, Rit 9 1803 66 116 1170 990000 483 1165 < 50
Pt 17 AZT, 3TC 49 1872 412 51 1155 110000 693 1359 150
Pt 18 AZT, ddl 268 1615 558 340 994 35000 989 1172 < 50
Pt 19 AZT, 3TC 393 819 206 559 1230 70319 616 825 < 50
Pt 20 AZT, 3TC 15 2503 21 235 877 230000 566 1246 < 50
Pt 22 D4T, 3TC 0 1807 64 290 140000 1334 < 50
Pt 23 AZT, 3TC 483 2109 248 409 734 47000 686 572 < 50
Pt 25 D4T,3TC, IDV 22 1661 625 383 809 37000 896 1208 < 50
Pt 26 AZT, 3TC 38 841 1150 540 1256 16000 719 640 < 50
Pt 27 AZT,3TC 10 1885 50 332 2800 636 < 50
Pt 28 AZT,3TC,EFV 0 3131 373 556 1900 752 < 50
Pt 29 AZT,3TC,Lop/rit 21 1950 69 483 150000 1233 100
Pt 31 AZT,3TC,IDV 0 1255 109 574 1625 7900 813 640 < 50
Pt 32 AZT,3TC,IDV 0 1472 160 393 1335 1235 < 50
Pt 33 D4T, 3TC 407 523 66 479 494 473 705 450 < 50
Pt 34 ddl, D4T, NVP 13 2207 54 493 1628 230000 907 943 < 50
Pt 38 AZT,3TC,LPV 0 1460 270 481 1156 20000 534 964 < 50
Pt 39 AZT,3TC,NVP 64 2734 767 539 41000 859 < 50
Pt 41 AZT,3TC,Lop/rit 62 428 89 200 135000 848 < 50
Clinical information about the twenty-one patients selected at the Clinical Department of the National Institute for Infectious Disease “L. Spallanzani” in Rome. All
subjects received HAART during chronic phase of infection.
†AZT, Retrovir (Zidovudine); 3TC, Epivir (Lamivudine); D4T, Zerit (Staduvine); SQV, Saquinvir (Invirase); Zalcitabina (ddC, Hivid); Rit, Ritonavir (Norvir); ddl,
Didanosine (Videx); IDV, Indinavir (Crix-ivan); EFV, Efavirenz; NVP, Nevirapine (Viramune); LPV (Lop), Lopinavir;
‡ Days elapsed from diagnosis (enrollment) to
initiation of HAART. *CD4 and CD8 are per microlitre of plasma, viremia is per millilitre of plasma.
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Page 4 of 9find no statistical difference in viral rebound between
early and late-treated patients (P ≥ 0.05, Mann-Whitney
U two-tailed test) confirming the results of [4]. In addi-
tion, we observe that a difference does exist for very
early initiation of therapy (P < 0.05, Mann-Whitney U
two-tailed test).
In the present work we extend the simulations of [4]
to include the new clinical settings corresponding to a
very early initiation of therapy. In particular, the very
early simulation settings correspond to a beginning of
the therapy within the first week whereas the late set-
tings correspond to initiating therapy between week five
and six from infection.
Figure 2 summarizes data of virological rebound
(averages) after therapy interruption at different time
points (4, 8 and 24 weeks) for very early and late patients
for both clinical (empty boxes) and simulation data (filled
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Figure 1 Plasma HIV-1 RNA load. The mean plasma HIV-1 RNA
load versus time in weeks after interruption of HAART for patients
classified in late (21 subjects), early (22 subjects) and very early (11
subjects) groups. Error bars show standard deviations. The features
of the three clinical settings are given in section Patients and
Methods.
Figure 2 Virological rebound. Virological rebound after 4 weeks (top), 8 weeks (middle) and 24 weeks (bottom) from therapy interruption for
two groups: very early (green boxes) that started HAART before seroconversion and late (blue boxes) that started HAART during chronic phase
of primary HIV-1 infection. Filled boxes represent in silico data (resulting from three thousands runs) whereas empty boxes correspond to in vivo
data. We have calculated the Mann-Whitney U test statistics for assessing whether the two independent samples (in silico and in vivo) come
from the same distribution. In all cases we did not find a significant difference (P ≥ 0.05, Mann-Whitney U two-tailed test). Black lines indicate
standard deviations. Information on parameter settings for the simulations can be found in the Additional file 1.
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Page 5 of 9boxes). Firstly, the figure shows that clinical and simula-
tion data are in good agreement (differences are not statis-
tically significant: P ≥ 0.05, Mann-Whitney U two-tailed
test). Secondly, the difference in plasma HIV-1 RNA
(copies/ml) between very early and late-treated patients
decreases with increasing time from therapy interruption.
Panel (a) shows a difference of about two logs with panel
(b) for both clinical data and simulations. These differ-
ences vanish after 24 weeks from therapy interruption (cfr.
panel (e) and (f)). The overall message is that a delay in
the initiation of therapy reduces the chances of maintain-
ing a therapy effect at discontinuation.
In order to provide a more precise estimate of the
time “limit” beyond which the benefit of an early initia-
tion of therapy vanishes, we use the simulation to inves-
tigate the influence of HAART initiation time (ts) on the
viral rebound. The corresponding results are shown in
Figure 3. The virological rebound at one week after ther-
apy interruption as a function of ts is presented. We
observe that there are two regimens, one for ts <2 0
days and one for ts > 30 corresponding to what clini-
cians call respectively best controllers (with undetectable
HIV RNA levels) and rebounders (whose HIV viremia
load returns, approximately, to the pre-HAART level).
The points in Figure 3 fit pretty well a generalized
logistic function (i.e., the Richards’ curve, [15]) describ-
ing the growth of viremia as a function of ts,
Vt a
ka
e
s dt t ss
()
()
* =+
−
+
−− 1
where the parameter k is the carrying capacity or the
upper asymptote, a is the lower asymptote, d is the
growth rate, and t s
* is the time of maximum growth. By
moving the time of the measurements beyond one week
after therapy interruption, the resulting data still fit the
same V (ts) but with a greater a, a smaller d and a
greater t s
*. In particular the limit for d going to zero, of
V (ts)i s( a + k)/2 may lead to the deceiving conclusion
that there is no window of opportunity because the viral
rebound is independent from ts.
With respect to t s
*, the value of~ 23:5 days points to
the early inflammation as a critical phase of the disease.
To bring into focus this facet, we compare two simu-
lated “markers” of the inflammation state in untreated
(control case), very early and lately treated simulated
patients (see Figure 4). These virtual markers are given
by the cell counts of active macrophages (a) and dendri-
tic cells presenting viral proteins on class II MHC mole-
cules (b). We observe that the late-treated case is
comparable to the control case (untreated) whereas the
very early stands on its own. This observation suggests
that it is the activation of the immune system through
the set up of an in ammatory state that has to be
blamed for the increased viral rebound for ts >t s
*.
Figure 4 shows with clarity that very early initiation of
the treatment can down-regulate the immune activation,
hence limiting viral replication and spread. Interestingly,
this view is supported by the observation that HIV trig-
gers the immune activation directly (e.g., HIV gene pro-
ducts can induce the activation of lymphocytes and
macrophages as well as the production of pro-inflamma-
tory cytokines and chemokines [2]) or indirectly (e.g.,
sustained antigen-mediated immune activation occurs in
HIV-1-infected patients due also to other viruses like
the cytomegalovirus or the Epstein-Barr virus [2]). In
both case, the result is a high level of pro-inflammatory
cytokines, such as tumor necrosis factor alpha, interleu-
kin 6 and interleukin 1 beta, right from the early stages
of HIV-1 infection [2].
Discussion
Recent analysis (performed by Fiebig et al. [16]) of sam-
ples from individuals that have been infected by HIV-1
has revealed that patients can be categorized into six
stages on the basis of a sequential gain in positive HIV-
1 clinical diagnostic assays (viral RNA measured by
PCR, p24 and p31 viral antigens measured by enzyme-
linked immunosorbent assay (ELISA), HIV-1-specific
antibody detected by ELISA and HIV-1-specific antibo-
dies detected by western blot, [16]). Patients progress
from acute to early chronic infection at the end of stage
Figure 3 Virological rebound after 1 weeks. Virological rebound
at 1 week after therapy interruption for different starting time
points of HAART (ts). The red dots represent the results of
thousands simulations and the fitting line is given by the Richards’
curve in equation 1. Standard deviation is about 0.1 log10(copies/ml)
for all points. Inset plot is a zoom for ts < 30 days. Parameters of
the fitting curve are: a = 1.52, k = 3.79, d = 0.12, and t s
* = 23.50.
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Page 6 of 9V, approximately 100 days following infection, as the
plasma viral load begins to stabilize.
With respect to the study conducted by clinical data
analysis and computer simulation described so far, we
identify three regimens, as highlighted in Figure 3.
These can be paralleled to Fiebig et al. stages [16]. In
particular, we observe that patients treated with
HAART in very early stages of the infection (stage I-III)
are likely to better control the viremia after treatment
interruption [3]. If therapy starts in the acute phase
(stage V-VI) then the action of the drug foils the
immune response and, as a consequence, at the end of
the therapeutic period, the virus rebounds undisturbed.
These considerations are summarized in Figure 5
where we draw a schematic picture of the importance of
an early initiation of HAART with respect to the progres-
sion of HIV markers according to Fiebig’s et al. stages. In
particular we identified the “window of opportunity” cor-
responding to stages I-III, that is, the first three weeks
from primary HIV-1 infection. Patients receiving therapy
in this narrow period are likely to turn out to be best
controllers. Probably, the massive immune activation in
the early stage of the disease favors the virus, as it finds
more host target cells to exploit for replication. In point
of fact, the ensuing massive depletion of CD4+ T cells in
mucosal lymphoid tissues, can result in the disruption of
the mucosal barrier in the gut. This barrier prevents the
translocation of the intestinal flora from the gut to the
systemic immune system restricting it to the lamina pro-
pia and the mesenteric lymph nodes [2]. HIV-1 infection
is indeed associated with a significant increase of plasma
lipopolysaccharide levels that is an indicator of microbial
translocation, directly correlated with measures of
immune activation.
Conclusions
A number of studies indicate that interfering with HIV
replication by starting the therapy in the early phases of
the infection could have a deep impact on the whole
disease course. However, HAART is costly, it is onerous
for both patient and health care provider, and often
brings adverse effects. Its clinical benefit must therefore
be weighed against its burden.
In the present study, we resorted to a computer model
to study the dynamics of the plasma viral load after pro-
longed treatment interruption in two groups of in silico
patients: those who initiate HAART very early and those
who start it lately. We evaluated the model comparing
the results to clinical data. We found that an opportu-
nity time-window exists for the initiation of HAART
(roughly within three weeks before the establishment of
viral reservoirs), in which the therapy can control viral
replication, preventing generalized immune activation
and extensive CD4+ T cell depletion.
Availability and requirements
An educational version of the immune system simulator
is available on our website:
- Name: C-ImmSim
- Home page: http://www.iac.rm.cnr.it/~filippo/C-
ImmSim.html
Figure 4 Inflammatory response. Cell counts of active macrophages (a) and dendritic cells presenting viral proteins on class II MHC molecules
(b) show that, in the simulation, the late-treated case is comparable to the control case (untreated) whereas the very early case stands on its
own. This suggests that the set up of an infiammatory state affects the viral rebound at therapy discontinuation. Counts are taken at week 8 for
all groups. Therapy for very early started within the first week and for the late started at about week 6.
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Page 7 of 9- Operating system(s): Linux, Unix Mac OS X,
Windows
- Programming language: C
- Licence: C-ImmSim is available under a LICENSE
AGREEMENT that needs to be signed: http://www.
iac.rm.cnr.it/~filippo/how-to-get-cimmsim_files/
LicenseAgreement.pdf
Additional material
Additional file 1: Mathematical model details. This file lists all the
interactions between cells and molecules considered in the model and
an accurate description of the parameter setting.
Additional file 2: Parameters tuning for the simulation of HIV
infected virtual patients. This file reports details of the parameter
setting and tuning.
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